Ascending aortic diameter
no changein mice1upin mice1
Angiotensin ii has no effect on ascending aortic diameter in mice.
“treated with AngII (1500 ng/kg/min) or saline, with no change in aortic size over the 4 week study period.”
Animalsaorta1500 ng/kg/min4 weeksn = 22
TESTING THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN AGE-RELATED HYPERTENSIVE AORTIC DISEASE
GSA 2024 abstract31 Dec 2024
Angiotensin ii increases ascending aortic diameter in mice (1.603 +/- 0.054 mm versus 1.433 +/- 0.064 mm, p< 0.05).
“These data revealed a statistically significant increase in ascending aortic size for AngII doses ⩾1000 ng/kg/min”
Animalsdoses >= 1000 ng/kg/minaorta4 weeksn = 8
TESTING THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN AGE-RELATED HYPERTENSIVE AORTIC DISEASE
GSA 2024 abstract31 Dec 2024
Inflammation
upin human cells1
Angiotensin ii induces inflammation in human cells.
“Finally, Ang II and miR-34a induce the upregulation of pro-inflammatory genes, interleukin (IL)-6, cyclooxygenase 2 (COX2), monocyte chemoattractant protein-1 (MCP-1)”
Cellsoverexpression of AGTRAP abolishes pro-inflammatory upregulationaorta
Angiotensin II, miR-34a, and AGTRAP crosstalk in arterial smooth muscle cells
GeroScience26 Nov 2025
AGTRAP
downin human cells1
Angiotensin ii decreases AGTRAP in human cells.
“Ang II enhances miR-34a in old rat VSMC and human aortic smooth muscle cells (HASMC), and inhibits AGTRAP and sirtuin 1 (SIRT1) mRNA/protein expression.”
Cellsaorta
Angiotensin II, miR-34a, and AGTRAP crosstalk in arterial smooth muscle cells
GeroScience26 Nov 2025
Cardiac fibrosis
upin mice1
Angiotensin ii increases cardiac fibrosis in mice.
“AII promotes inflammatory/profibrotic signaling, which contributes to fibrosis and impairs systolic function in aging males.”
Animalsosmotic minipump infusionventricle3 mg/kg/day6 weeksmales
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
GeroScience7 Nov 2025
Ventricular wall thickness
upin mice1
Angiotensin ii increases ventricular wall thickness in mice.
“AII increased wall thickness in females but reduced it and caused left ventricular (LV) dilation in males only.”
Animalsosmotic minipump infusionheart3 mg/kg/day6 weeksfemales
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
GeroScience7 Nov 2025
Blood pressure
upin mice1
Angiotensin ii increases blood pressure in mice.
“AII treatment increased BP and heart weight/tibia length in both sexes.”
Animalsosmotic minipump infusion3 mg/kg/day6 weeks
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
GeroScience7 Nov 2025
Isovolumic contraction time
upin mice1
Angiotensin ii increases isovolumic contraction time in mice (12.0 ± 0.7 vs. 24.3 ± 3.0 ms).
“isovolumic contraction time (IVCT) increased (12.0 ± 0.7 vs. 24.3 ± 3.0 ms; p = 0.0001)”
Animalsosmotic minipump infusionheart3 mg/kg/day6 weeksmales
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
GeroScience7 Nov 2025
Ejection fraction
downin mice1
Angiotensin ii decreases ejection fraction in mice (68.9 ± 1.9 vs. 46.1 ± 4.5).
“ejection fraction (EF) declined in males (68.9 ± 1.9 vs. 46.1 ± 4.5; p = 0.0001), which indicates marked systolic dysfunction.”
Animalsosmotic minipump infusionheart3 mg/kg/day6 weeksmales
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
GeroScience7 Nov 2025
Maximal oxygen consumption rate
no changein mice1
Angiotensin ii has no effect on maximal oxygen consumption rate in mice (30 +/- 3.6 versus 29.4 +/- 0.9 pmol/(sec*mg), p=0.99).
“The older cohort also revealed no difference in maximal oxygen consumption rate (OCR) between the AngII and saline groups”
Animalsaorta1500 ng/kg/min4 weeks
TESTING THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN AGE-RELATED HYPERTENSIVE AORTIC DISEASE
GSA 2024 abstract31 Dec 2024
La Jolla Pharmaceutical Company
Company3 trialsPhase 3446 people
Chia Tai Tianqing Pharmaceutical Group
Company1 trialPhase 3214 people
Wake Forest University Health Sciences
2 trialsPhase 4110 people
Methodist Healthcare System of San Antonio
1 trialPhase 4329 people
University of Maryland St. Joseph Medical Center
1 trialPhase 4100 people
1 trialPhase 442 people
1 trialPhase 430 people
1 trialPhase 430 people
National Heart, Lung, and Blood InstituteUS$1.2mNational Institute on AgingUS$1.4m
Cardiomyocyte TRPV4 and Angiotensin-II induced ventricular arrhythmia with aging
National Heart, Lung, and Blood InstituteUniversity of Missouri-ColumbiaUS$402.6k2017–2028
The Impact of Sex and Hippocampal Angiotensin II on Alzheimer's Disease
National Institute on AgingUniversity of North Texas Hlth Sci CtrUS$714.6k2024–2029
The two-year combined outcome rate was 15.6% for sodium-glucose cotransporter 2 inhibitors versus 19.9% for renin-angiotensin system inhibitors, the comparison drug…The two-year combined outcome rate was 15.6% for sodium-glucose cotransporter 2 inhibitors versus 19.9% for renin-angiotensin system inhibitors, the comparison drug class.
Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).Incidence of all-cause dementia was 1.26 per 1000 person-years with RAS inhibitors versus 1.89 with calcium channel blockers (HR 0.68).
Mice lacking the receptor also showed higher inflammation, elevated DNA damage, and a five-month reduction in median lifespan.Mice lacking the receptor also showed higher inflammation, elevated DNA damage, and a five-month reduction in median lifespan.